HUP9801817A2 - Dolasztatinszármazékok, előállításuk és felhasználásuk - Google Patents

Dolasztatinszármazékok, előállításuk és felhasználásuk

Info

Publication number
HUP9801817A2
HUP9801817A2 HU9801817A HUP9801817A HUP9801817A2 HU P9801817 A2 HUP9801817 A2 HU P9801817A2 HU 9801817 A HU9801817 A HU 9801817A HU P9801817 A HUP9801817 A HU P9801817A HU P9801817 A2 HUP9801817 A2 HU P9801817A2
Authority
HU
Hungary
Prior art keywords
glycyl
methyl
leucyl
tert
propyl
Prior art date
Application number
HU9801817A
Other languages
English (en)
Inventor
Franz Emling
Andreas Haupt
Cynthia A. Romerdahl
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of HUP9801817A2 publication Critical patent/HUP9801817A2/hu
Publication of HUP9801817A3 publication Critical patent/HUP9801817A3/hu
Publication of HU228073B1 publication Critical patent/HU228073B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A találmány tárgyát az R1R2N-CHX-CO-A-B-D-E-(F)t-K (I) általánősképletű új peptidek -, ahől R1 metil-, etil- vagy izőprőpilcsőpőrt, R2 hidrőgénatőm, metil- vagy etilcsőpőrt, R1R2N- együttpirrőlidingyűrű lehet, A valil-, izőleűcil-, leűcil-, 2-terc-bűtil-glicil-, 2-etil-glicil-,nőrleűcil- vagy nőrvalilmaradék, B N-metil-valil-, -leűcil-, -izőleűcil-, -nőrvalil-, nőrleűcil-, -2-terc-bűtil-glicil-, -3-terc-bűtil-alanil- vagy 2-etil-glicil-maradék, D prőlil-, 3,4-dehidrőprőlil-, 4-flűőr-prőpil-, 4,4-diflűőr-prőpil-,azetidin-2-karbőnil-, hőmőprőlil-, 3-metil-prőlil-, 4-metil-prőlil-vagy 5-metil-prőlil- vagy tiazőlidin-4-karbőnil-maradék, E 3,4-dehidrőprőlil-, 4-flűőr-prőlil-, 3-mnetil-prőlil-, 4-metil-prőlil-, azetidin-2-karbőnil- vagy 4,4-diflűőr-prőlil-maradék, F valil-, 2-terc-bűtil-glicil-, izőleűcil-, leűcil-, 2-ciklőhexil-glicil-, nőrleűcil-, nőrvalil-, neőpentil-glicil-, -alanil- vagyaminő-izőbűtiril-maradék, X alkil- (előnyösen 2-5 szénatőmős), ciklőprőpil- vagy ciklőpentil-csőpőrt, t 0 vagy 1, K alkőxi- (előnyösen 1-4 szénatőmős), benzil-őxi- vagy szűbsztitűáltvagy szűbsztitűálatlan aminőcsőpőrt - és fiziőlógiásan elviselhetősavakkal sóik képezik. A találmány szerinti új peptidek daganatgátlóhatással rendelkeznek. ŕ
HU9801817A 1995-06-07 1996-06-03 Új dolasztatin-származékok, elõállításuk, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények HU228073B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002393 WO1996040752A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (3)

Publication Number Publication Date
HUP9801817A2 true HUP9801817A2 (hu) 1998-11-30
HUP9801817A3 HUP9801817A3 (en) 1999-06-28
HU228073B1 HU228073B1 (hu) 2012-09-28

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9801910A HU228071B1 (hu) 1995-06-07 1996-06-03 Dolasztatinszármazékok, elõállításuk és felhasználásuk
HU9801817A HU228073B1 (hu) 1995-06-07 1996-06-03 Új dolasztatin-származékok, elõállításuk, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9801910A HU228071B1 (hu) 1995-06-07 1996-06-03 Dolasztatinszármazékok, elõállításuk és felhasználásuk

Country Status (33)

Country Link
US (1) US5831002A (hu)
EP (2) EP0871656B1 (hu)
JP (2) JP4221062B2 (hu)
KR (2) KR100437985B1 (hu)
CN (2) CN1182154C (hu)
AR (2) AR003427A1 (hu)
AT (2) ATE224910T1 (hu)
AU (2) AU725170B2 (hu)
BG (2) BG102125A (hu)
BR (2) BR9609423A (hu)
CA (2) CA2219818C (hu)
CO (2) CO4700527A1 (hu)
CZ (2) CZ293682B6 (hu)
DE (2) DE69623992T2 (hu)
DK (2) DK0832104T3 (hu)
ES (2) ES2186783T3 (hu)
HR (2) HRP960257A2 (hu)
HU (2) HU228071B1 (hu)
IL (2) IL122215A (hu)
MX (2) MX9709147A (hu)
MY (2) MY119042A (hu)
NO (2) NO318384B1 (hu)
NZ (2) NZ310444A (hu)
PL (2) PL185762B1 (hu)
PT (2) PT871656E (hu)
RO (2) RO118953B1 (hu)
SI (2) SI0832104T1 (hu)
SK (1) SK282466B6 (hu)
TR (2) TR199701545T1 (hu)
TW (2) TW508357B (hu)
UA (2) UA46776C2 (hu)
WO (2) WO1996040751A1 (hu)
ZA (2) ZA964710B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7018642B2 (en) 2001-04-27 2006-03-28 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1924245A2 (en) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CN101674835B (zh) * 2007-04-12 2013-12-11 台湾神隆股份有限公司 制备加兰他敏的方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA201391756A1 (ru) * 2011-05-27 2014-05-30 Амбркс, Инк. Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
HUP9801910A3 (en) 1999-06-28
ATE224910T1 (de) 2002-10-15
IL122215A (en) 2001-08-26
DK0871656T3 (da) 2003-01-27
AU725164B2 (en) 2000-10-05
SK165397A3 (en) 1998-10-07
DE69623472T2 (de) 2003-08-21
NO975710D0 (no) 1997-12-05
NO975710L (no) 1998-02-02
MY124487A (en) 2006-06-30
US5831002A (en) 1998-11-03
PT871656E (pt) 2002-12-31
CA2219819A1 (en) 1996-12-19
HU228071B1 (hu) 2012-09-28
UA46775C2 (uk) 2002-06-17
CZ376397A3 (cs) 1998-06-17
PL185763B1 (pl) 2003-07-31
EP0871656B1 (en) 2002-09-25
ES2188759T3 (es) 2003-07-01
CN1182154C (zh) 2004-12-29
JPH11504652A (ja) 1999-04-27
CN1187198A (zh) 1998-07-08
RO118953B1 (ro) 2004-01-30
UA46776C2 (uk) 2002-06-17
DK0832104T3 (da) 2003-01-06
HU228073B1 (hu) 2012-09-28
KR19990022582A (ko) 1999-03-25
PL185762B1 (pl) 2003-07-31
PL323723A1 (en) 1998-04-14
TR199701545T1 (xx) 1998-04-21
DE69623992D1 (de) 2002-10-31
TR199701544T1 (xx) 1998-03-21
IL122216A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
NZ310443A (en) 1999-10-28
SI0871656T1 (en) 2003-08-31
ZA964710B (en) 1997-12-08
CN1187199A (zh) 1998-07-08
BR9609423A (pt) 1999-06-29
IL122216A (en) 2002-02-10
IL122215A0 (en) 1998-04-05
MX9709146A (es) 1998-03-31
BG102125A (en) 1998-09-30
DE69623472D1 (de) 2002-10-10
NO317670B1 (no) 2004-11-29
EP0832104B1 (en) 2002-09-04
CZ376597A3 (cs) 1998-06-17
WO1996040751A1 (en) 1996-12-19
WO1996040752A1 (en) 1996-12-19
ZA964711B (en) 1997-12-08
AR003136A1 (es) 1998-07-08
NO975711D0 (no) 1997-12-05
NO975711L (no) 1998-01-30
HUP9801817A3 (en) 1999-06-28
DE69623992T2 (de) 2003-05-22
TW508357B (en) 2002-11-01
AR003427A1 (es) 1998-08-05
NO318384B1 (no) 2005-03-14
BR9609424A (pt) 2000-03-28
CO4700526A1 (es) 1998-12-29
NZ310444A (en) 1999-11-29
JP3957751B2 (ja) 2007-08-15
PL323726A1 (en) 1998-04-14
SI0832104T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
CZ293682B6 (cs) 2004-07-14
KR100437986B1 (ko) 2004-09-18
MY119042A (en) 2005-03-31
PT832104E (pt) 2002-12-31
KR19990022583A (ko) 1999-03-25
HRP960257A2 (en) 1998-02-28
CN1182153C (zh) 2004-12-29
HRP960277A2 (en) 1997-10-31
CA2219818A1 (en) 1996-12-19
TW424096B (en) 2001-03-01
EP0832104A1 (en) 1998-04-01
ES2186783T3 (es) 2003-05-16
MX9709147A (es) 1998-03-31
EP0871656A1 (en) 1998-10-21
JPH11504653A (ja) 1999-04-27
KR100437985B1 (ko) 2004-09-18
AU6124296A (en) 1996-12-30
ATE223431T1 (de) 2002-09-15
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
CZ293683B6 (cs) 2004-07-14
AU6124196A (en) 1996-12-30
CA2219819C (en) 2008-05-20
BG102152A (en) 1998-09-30
CO4700527A1 (es) 1998-12-29
RO119783B1 (ro) 2005-03-30
SK282466B6 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
HUP9801817A2 (hu) Dolasztatinszármazékok, előállításuk és felhasználásuk
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
HUP0004853A2 (hu) Hepatitis C inhibitor peptidek, eljárás ezek előállítására, azokat tartalmazó gyógyszerkészítmények, alkalmazásuk és intermediereik
HUP9700602A1 (hu) A csontreszorpció és vitronektin receptor-antagonisták új inhibitorai
SE9100342D0 (sv) Novel steroid esters
NO861723L (no) Fremgangsmaate for fremstilling av nye tetrapyrrolderivater
HUP0001758A2 (hu) C-terminálison karbonil és heterociklusos funkciós csoportokkal rendelkező dolasztatin-15-származékok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
DE3564566D1 (en) Quinone derivatives, method and use of preparing same, and pharmaceutical composition
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG104445A (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
MX9206150A (es) Agentes antiinflamatorios de derivados de tripeptidos
IT1249732B (it) Oligonucleotidi antisenso.
GB2380939B (en) Treatment or prevention of auto-immune diseases
NO172437C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidindionforbindelser
ES2164869T3 (es) Conjugados lipidos especificos de nucleosidos-difosfato y su uso como medicamentos.
HUP9802407A1 (hu) Eljárás kamptotecinszármazékok előállítására, valamint a közbenső termékként szolgáló vegyületek
ES460618A1 (es) Procedimiento para la preparacion de derivados de peptido
HUP9702293A2 (hu) 4-Tiazolidinon-, rodanin- és 1,3-oxatiolán-5-on-származékok alkalmazása sclerosis multiplex kezelésére alkalmas gyógyszerkészítmények előállítására
MY111439A (en) Thymosin alpha 1 derivatives
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
ES471672A1 (es) Un procedimiento para la preparacion de un peptido
HUP9903424A1 (hu) Új eritromicinszármazékok,eljárás előállításukra és gyógyszerként való alkalmazásuk
KR910000790A (ko) 고리형 테트라펩티드 및 그의 제조방법

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, DE

Free format text: FORMER OWNER(S): ABBOTT GMBH & CO. KG, DE; BASF AKTIENGESELLSCHAFT, DE

MM4A Lapse of definitive patent protection due to non-payment of fees